CO2020016582A2 - Sales de sepiapterina farmacéuticamente aceptables - Google Patents
Sales de sepiapterina farmacéuticamente aceptablesInfo
- Publication number
- CO2020016582A2 CO2020016582A2 CONC2020/0016582A CO2020016582A CO2020016582A2 CO 2020016582 A2 CO2020016582 A2 CO 2020016582A2 CO 2020016582 A CO2020016582 A CO 2020016582A CO 2020016582 A2 CO2020016582 A2 CO 2020016582A2
- Authority
- CO
- Colombia
- Prior art keywords
- sepiapterin
- salts
- pharmaceutically acceptable
- cocrystals
- relates
- Prior art date
Links
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical class N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 title abstract 5
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940126478 sepiapterin Drugs 0.000 abstract 3
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 abstract 1
- 229960004617 sapropterin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/06—Glycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678025P | 2018-05-30 | 2018-05-30 | |
| US201862726612P | 2018-09-04 | 2018-09-04 | |
| US201962822336P | 2019-03-22 | 2019-03-22 | |
| GC201937661 | 2019-05-28 | ||
| PCT/US2019/034505 WO2019232120A1 (en) | 2018-05-30 | 2019-05-30 | Pharmaceutically acceptable salts of sepiapterin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020016582A2 true CO2020016582A2 (es) | 2021-04-08 |
Family
ID=68699017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0016582A CO2020016582A2 (es) | 2018-05-30 | 2020-12-29 | Sales de sepiapterina farmacéuticamente aceptables |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210269443A1 (https=) |
| EP (1) | EP3807279B1 (https=) |
| JP (2) | JP7778477B2 (https=) |
| KR (1) | KR20210038848A (https=) |
| CN (1) | CN112543758A (https=) |
| AU (2) | AU2019277372B2 (https=) |
| BR (1) | BR112020024332A2 (https=) |
| CA (1) | CA3102070A1 (https=) |
| CL (1) | CL2020003101A1 (https=) |
| CO (1) | CO2020016582A2 (https=) |
| IL (1) | IL279101A (https=) |
| MX (1) | MX2020012978A (https=) |
| WO (1) | WO2019232120A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| EP3801536B1 (en) | 2018-05-30 | 2024-07-17 | PTC Therapeutics MP, Inc. | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| CN112654356A (zh) * | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| CN114621198B (zh) | 2020-12-11 | 2025-01-21 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| JP2024506336A (ja) | 2021-02-09 | 2024-02-13 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 膠芽腫の治療方法 |
| EP4291196A1 (en) | 2021-02-09 | 2023-12-20 | PTC Therapeutics MP, Inc. | Methods for treating covid-19 with sepiapterin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| ATE218345T1 (de) * | 1994-08-05 | 2002-06-15 | Suntory Ltd | Arzneimittel gegen spinocerebellare degeneration |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| WO2008128049A2 (en) * | 2007-04-11 | 2008-10-23 | Biomarin Pharmaceutical Inc. | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| IN2014DN09053A (https=) | 2012-05-07 | 2015-05-22 | Shiratori Pharm | |
| WO2017218421A1 (en) * | 2016-06-13 | 2017-12-21 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| US11130760B2 (en) * | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| US11072614B2 (en) * | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
-
2019
- 2019-05-30 AU AU2019277372A patent/AU2019277372B2/en active Active
- 2019-05-30 CA CA3102070A patent/CA3102070A1/en active Pending
- 2019-05-30 CN CN201980050845.2A patent/CN112543758A/zh active Pending
- 2019-05-30 BR BR112020024332-9A patent/BR112020024332A2/pt unknown
- 2019-05-30 US US17/059,887 patent/US20210269443A1/en active Pending
- 2019-05-30 JP JP2020566701A patent/JP7778477B2/ja active Active
- 2019-05-30 EP EP19811127.0A patent/EP3807279B1/en active Active
- 2019-05-30 WO PCT/US2019/034505 patent/WO2019232120A1/en not_active Ceased
- 2019-05-30 KR KR1020207037815A patent/KR20210038848A/ko not_active Ceased
- 2019-05-30 MX MX2020012978A patent/MX2020012978A/es unknown
-
2020
- 2020-11-27 CL CL2020003101A patent/CL2020003101A1/es unknown
- 2020-11-30 IL IL279101A patent/IL279101A/en unknown
- 2020-12-29 CO CONC2020/0016582A patent/CO2020016582A2/es unknown
-
2024
- 2024-02-29 JP JP2024030700A patent/JP7841008B2/ja active Active
-
2025
- 2025-02-13 AU AU2025201002A patent/AU2025201002A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019277372A1 (en) | 2021-01-21 |
| EP3807279A4 (en) | 2022-04-06 |
| CL2020003101A1 (es) | 2021-05-14 |
| CA3102070A1 (en) | 2019-12-05 |
| IL279101A (en) | 2021-01-31 |
| AU2025201002A1 (en) | 2025-03-06 |
| CN112543758A (zh) | 2021-03-23 |
| WO2019232120A1 (en) | 2019-12-05 |
| JP7841008B2 (ja) | 2026-04-06 |
| EP3807279B1 (en) | 2025-12-31 |
| JP2021527031A (ja) | 2021-10-11 |
| US20210269443A1 (en) | 2021-09-02 |
| KR20210038848A (ko) | 2021-04-08 |
| MX2020012978A (es) | 2021-04-28 |
| BR112020024332A2 (pt) | 2021-02-23 |
| AU2019277372B2 (en) | 2024-12-19 |
| EP3807279A1 (en) | 2021-04-21 |
| JP7778477B2 (ja) | 2025-12-02 |
| JP2024063143A (ja) | 2024-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020016582A2 (es) | Sales de sepiapterina farmacéuticamente aceptables | |
| CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
| CL2018001996A1 (es) | Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16) | |
| MX383856B (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| JOP20180113B1 (ar) | مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX377919B (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| CY1122042T1 (el) | Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο | |
| UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet |